Based on 10 Wall Street analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $13.23 with a high forecast of $35.00 and a low forecast of $4.40. The average price target represents a 335.20% change from the last price of $3.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","36":"$36","9.75":"$9.75","18.5":"$18.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$13.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$4.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.75,18.5,27.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.96,6.3476923076923075,8.735384615384614,11.123076923076923,13.510769230769231,15.89846153846154,18.286153846153844,20.673846153846153,23.06153846153846,25.44923076923077,27.836923076923078,30.224615384615383,32.61230769230769,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.96,4.673076923076923,5.386153846153846,6.099230769230769,6.812307692307693,7.525384615384615,8.23846153846154,8.951538461538462,9.664615384615384,10.377692307692307,11.09076923076923,11.803846153846154,12.516923076923078,{"y":13.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.96,3.993846153846154,4.027692307692308,4.061538461538461,4.095384615384615,4.1292307692307695,4.163076923076924,4.196923076923077,4.230769230769231,4.264615384615385,4.298461538461539,4.332307692307692,4.366153846153846,{"y":4.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.41,"date":1682035200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.42,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$13.23

Lowest Price Target$4.40

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Truist Financial

xxxxxxxxxxxxx

Reiterated

03/19/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

03/19/24

xxxxxxxxxxxxxxxxxx

H.C. Wainwright

xxxxxxxxxxxxx

Reiterated

03/19/24

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Reiterated

03/15/24

xxxxxxxxxxxxxxxxxx

William Blair

xxxxxxxxxxxxx

Assigned

03/15/24

xxxxxxxxxxxxxxxxxx

Robert W. Baird

xxxxxxxxxxxxx

Reiterated

03/15/24

xxxxxxxxxxxxxxxxxx

JMP Securities

xxxxxxxxxxxxx

Reiterated

03/15/24

xxxxxxxxxxxxxxxxxx

Canaccord Genuity

xxxxxxxxxxxxx

Reiterated

03/14/24

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Assigned

03/14/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

02/27/24

Michael Schmidt

Guggenheim

―

Hold

―

Downgraded

01/05/24

Allogene Therapeutics downgraded to Neutral from Buy at GuggenheimAllogene Therapeutics downgraded to Neutral from Buy at Guggenheim

Kalpit Patel

B.Riley Financial

$10.00

Buy

228.95%

Upside

Reiterated

01/05/24

Allogene (ALLO) PT Lowered to $10 at B.RileyB.Riley analyst Kalpit Patel lowered the price target on Allogene (NASDAQ: ALLO) to $10.00 (from $15.00) while maintaining a Buy rating.

Samantha Semenkow

Citi

$7.00

Buy

130.26%

Upside

Initiated

12/10/23

Buy Recommendation: Allogene Therapeutics' Undervalued Stock and Promising CAR-T Pipeline

William Pickering

Bernstein

$4.50

Hold

48.03%

Upside

Reiterated

11/03/23

Hold Rating for Allogene Therapeutics Amid Clinical Trials Progress and Financial Concerns

Hartaj Singh

Oppenheimer

$28.00

Buy

821.05%

Upside

Reiterated

08/03/23

Best Analysts Covering Allogene Therapeutics

Which Analyst Should I Follow If I Want to Buy ALLO and Sell After:

1 Month

Robert BurnsH.C. Wainwright

Success Rate

7/18 ratings generated profit

Average Return

+1.96%

reiterated a buy rating last month

Copying Robert Burns's trades and holding each position for 1 Month would result in 38.89% of your transactions generating a profit, with an average return of +1.96% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

John NewmanCanaccord Genuity

Success Rate

7/16 ratings generated profit

Average Return

+5.83%

reiterated a buy rating last month

Copying John Newman's trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of +5.83% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

John NewmanCanaccord Genuity

Success Rate

4/16 ratings generated profit

Average Return

-21.03%

reiterated a buy rating last month

Copying John Newman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.03% per trade.

2 Years

Robert BurnsH.C. Wainwright

Success Rate

2/18 ratings generated profit

Average Return

-49.74%

reiterated a buy rating last month

Copying Robert Burns's trades and holding each position for 2 Years would result in 11.11% of your transactions generating a profit, with an average return of -49.74% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALLO Analyst Recommendation Trends

Rating

Nov 23

Dec 23

Jan 24

Feb 24

Mar 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALLO has received 14 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ALLO average Analyst price target in the past 3 months is $13.23.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ALLO Financial Forecast

ALLO Earnings Forecast

Next quarter’s earnings estimate for ALLO is -$0.41 with a range of -$0.64 to -$0.22. The previous quarter’s EPS was -$0.51. ALLO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.61% of the time in the same period. In the last calendar year ALLO has Underperformed its overall industry.

ALLO Sales Forecast

Next quarter’s sales forecast for ALLO is $11.00K with a range of $0.00 to $50.00K. The previous quarter’s sales results were $21.00K. ALLO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.10% of the time in the same period. In the last calendar year ALLO has Outperformed its overall industry.

ALLO Stock Forecast FAQ

What is ALLO’s average 12-month price target, according to analysts?

Based on analyst ratings, Allogene Therapeutics Inc’s 12-month average price target is $13.23.

What is ALLO’s upside potential, based on the analysts’ average price target?

Allogene Therapeutics Inc has 335.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALLO a Buy, Sell or Hold?

Allogene Therapeutics Inc has a conensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.

What is Allogene Therapeutics Inc’s price target?

The average price target for Allogene Therapeutics Inc is $13.23. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $4.40. The average price target represents 335.20% Increase from the current price of $3.04.

What do analysts say about Allogene Therapeutics Inc?

Allogene Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of ALLO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

ALLO Analyst Ratings

ALLO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Allogene Therapeutics

ALLO Analyst Recommendation Trends

ALLO Financial Forecast

ALLO Earnings Forecast

ALLO Sales Forecast

ALLO Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts